Loading clinical trials...
Loading clinical trials...
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
Banner Alzheimer's Institute
Phoenix, Arizona, United States
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
Cherlin Research
Los Gatos, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
California Research Foundation
San Diego, California, United States
Pacific Research Network
San Diego, California, United States
Ray Dolby Brain Health Center
San Francisco, California, United States
Syrentis Clinical Research
Santa Ana, California, United States
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida, United States
Galiz Research
Hialeah, Florida, United States
Start Date
September 1, 2015
Primary Completion Date
June 13, 2018
Completion Date
July 15, 2018
Last Updated
September 7, 2020
156
ACTUAL participants
Flortaucipir F18
DRUG
PET Scan
PROCEDURE
Lead Sponsor
Avid Radiopharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07033494